ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PTN
INM (47) BFRG (32) CMMB (31) MBRX (34) ⌘ Pro Terminal →

Palatin Technologies Inc. (PTN) — RQD Stock Rating Cockpit

$4.99 -0.20% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.98

Palatin Technologies Inc. (PTN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $8.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PTN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PTN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Palatin Technologies Inc. (NASDAQ: PTN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $4.99 (-0.20% 1D, market cap $8.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PTN ranks #611 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PTN compare to INM and BFRG in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PTN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INM (InMed Pharmaceuticals Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $8.8M) and BFRG (Bullfrog AI Holdings Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $9.0M). Among the 5-stock peer group, PTN leads on earnings multiple (N/A) while PTN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PTN?
▼

Per PTN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000911216), Palatin Technologies Inc. generated $48.9M in revenue (+988.8% YoY), -$17.3M in net income, and -$21.3M in free cash flow against $17.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.98 (-0.23%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510035
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (3)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.4% Base Target
$33 Bull$4 Base$3 Bear
📬 FREE PTN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PTN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY PTN SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.2 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
43
Grade D$8.19-32.6% Next Q
Q2 (-2Q)
40
Grade D$5.52-13.6% Next Q
Q3 (-1Q)
38
Grade E$4.77+4.6% Next Q
Current
35
Grade D-$4.99-8.5% Hist 90D α
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PTN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PTN currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.95) and Max Pain ($5.24) forces dealer call-delta covering toward $32.55.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PTN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PTN Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERSOLD (<32)
26.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
1 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $5$4.99H: $31
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on PTN

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (30)

8/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like PTN
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PTN)

  • ✓Walkthrough of PTN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PTN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -75.10%🛡️ HOLDING TREND SUPPORT
2026-11-03O $4.93H $5.00L $4.93C $4.99VOL 16.0K
SUP: $4.04SMA50: $8.95SMA200: $13.92
$22.92$17.93$12.94$7.95$2.96SUP $4.04$4.992026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PTN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PTN Butterfly Map → + Track PTN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +988.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PTN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PTN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PTN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PTN)

Health Care Rank #611 of 1015 ⚔️ INM vs PTN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PTN vs. INM, BFRG, CMMB, MBRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Palatin Technologies Inc. (PTN) ranks #611 by composite RQD confidence (35/100, grade D-) and #901 by equity capitalization ($8.9M). Within this direct 5-issuer industry benchmark cohort, PTN leads on earnings valuation at N/A trailing P/E, while PTN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. INM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with PTN at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PTN ACTIVE
Palatin Technologies Inc.
D- 35/100 — — -35.0% -0.20% $8.9M Benchmark Subject
INM
InMed Pharmaceuticals Inc.
D 47/100 — 34.5% -35.0% +1.88% $8.8M /inm-vs-ptn →
BFRG
Bullfrog AI Holdings Inc.
E 32/100 — 18.8% -35.0% +1.78% $9.0M /bfrg-vs-ptn →
CMMB
Chemomab Therapeutics Ltd.
E 31/100 — — -35.0% +1.72% $9.3M /cmmb-vs-ptn →
MBRX
Moleculin Biotech Inc.
E 34/100 — — -35.0% +5.32% $8.3M /mbrx-vs-ptn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000911216 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Palatin Technologies Inc. (PTN) reported GAAP revenue of $48.9M (+988.8% vs. FY2024 revenue of $4.5M , and +907.2% cumulative change since FY2023) , GAAP net income of -$17.3M, operating cash flow of -$21.3M, and free cash flow of -$21.3M (+32.4% YoY). On the balance sheet, PTN closed FY2025 with $17.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $48.9M -$17.3M -$21.3M -$21.3M $17.9M —
FY2024 (FY) 2024-06-30 $4.5M $29.7M -$31.5M -$31.5M $4.3M —
FY2023 (FY) 2023-06-30 $4.9M $36.2M -$29.3M -$29.3M — —

3. PTN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PTN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Palatin Technologies Inc. (NASDAQ: PTN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $4.99 (-0.20% 1D, market cap $8.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PTN ranks #611 in composite RQD confidence.

How does PTN compare to INM and BFRG in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PTN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INM (InMed Pharmaceuticals Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $8.8M) and BFRG (Bullfrog AI Holdings Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $9.0M). Among the 5-stock peer group, PTN leads on earnings multiple (N/A) while PTN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PTN?

Per PTN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000911216), Palatin Technologies Inc. generated $48.9M in revenue (+988.8% YoY), -$17.3M in net income, and -$21.3M in free cash flow against $17.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PTN trading relative to its 50-day, 200-day, and 52-week technical levels?

PTN last traded at $4.99 (-0.20% on volume of 30,717 shares), positioning the stock -44.25% below its 50-day simple moving average ($8.95) and -64.15% below its 200-day simple moving average ($13.92). Across its 52-week range of $4.51 to $31.00, PTN sits at the 1.8% percentile with a 14-day RSI of 26.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.37 to $5.61).

Direct Sub-Reports: PTN RQD Cockpit PTN 12M Forecast PTN Earnings & Move PTN Dividends & DRIP PTN Insiders & 13F PTN Whale Options PTN Profit Sankey PTN News & Why
ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

PTN — Palatin Technologies Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Palatin Technologies Inc. (PTN) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.99 (-0.20% 1D, market capitalization $8.9M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Palatin Technologies Inc. (PTN) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Palatin Technologies Inc. (PTN) reported $48.9M in annual revenue (up from $4.5M in FY2024, +988.8% YoY) and -$17.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($4.9M revenue, $36.2M net income) through FY2025, PTN scaled operating cash flow to -$21.3M and free cash flow to -$21.3M, backed by $17.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $4.51 – $31.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links, no sector correlation mapping, and no proprietary signals recorded for PTN. The stock's sector placement (Health Care, Biotechnology: Pharmaceutical Preparations) is the only structural context available. Investors should watch for whether any pharma-sector developments referenced in news coverage translate into concrete counterparty relationships, though the source data cannot confirm this.

  • Key Question #1: Can PTN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $48.9M and free cash flow of -$21.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PTN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PTN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Palatin Technologies Inc. (PTN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PTN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PTN Bull vs. Bear Conversation Board — What's Your Call at $4.99?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PTN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PTN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $6.10 (+22.0%)
📌 Pinned Debate

The news feed flags a possible obesity-pipeline fit for big pharma, and the Roarable RQD rating shows a 1.0 beta and a 2.5 Altman Z-Sco

Picked up a starter position in PTN in my $100K Virtual Cash book at $5.00. The news feed flags a possible obesity-pipeline fit for big pharma, and the Roarable RQD rating shows a 1.0 beta and a 2.5 Altman Z-Score that places the balance sheet outside distress territory.. Trading inside a $4.51–$31.00 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@QuantViper Agree on the RQD 35/100 quality, though with 1.0 beta I'm scaling in with half-size at $5.00 and keeping dry powder in case we test $4.65.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $4.20 (-16.0%)
Spot @ $5.00

Operating income and free cash flow were negative in every reported period, ROIC is -35%, and the Piotroski F-Score of 1/9 signals weak

Here is the bear case nobody on the bull side wants to address on PTN: Operating income and free cash flow were negative in every reported period, ROIC is -35%, and the Piotroski F-Score of 1/9 signals weak fundamental quality.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%